Shopping Cart
- Remove All
Your shopping cart is currently empty
Saroglitazar Magnesium is a novel peroxissome proliferator-activated receptor (PPAR) agonist with significant activation activity against PPARα (EC50 0.65pM) and moderate activation against PPARγ (EC50 3 nM).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $53 | In Stock | |
| 5 mg | $139 | In Stock | |
| 10 mg | $215 | In Stock | |
| 25 mg | $343 | In Stock | |
| 50 mg | $463 | In Stock | |
| 100 mg | $592 | In Stock | |
| 200 mg | $783 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $213 | In Stock |
| Description | Saroglitazar Magnesium is a novel peroxissome proliferator-activated receptor (PPAR) agonist with significant activation activity against PPARα (EC50 0.65pM) and moderate activation against PPARγ (EC50 3 nM). |
| Targets&IC50 | PPARγ:3 nM (EC50, HepG2 cell), PPARα:0.65 pM (EC50, HepG2 cell) |
| In vivo | In db/db mice, Saroglitazar (0.01-3 mg/kg per day, orally) treatment with 12-day causes dose-dependent reductions in serum triglycerides (TG), free fatty acids (FFA), and glucose. The ED50 for these effects is found to be 0.05, 0.19, and 0.19 mg/kg, respectively with highly significant (91%) reduction in serum insulin and AUC-glucose following oral glucose administration (59%) at 1 mg/kg dose.in Wistar rats and marmosets A 90-day repeated dose comparative study confirms efficacy (TG lowering) potential of Saroglitazar and has indicated low risk of PPAR-associated side effects in humans. Based on efficacy and safety profile, Saroglitazar appears to have good potential as novel therapeutic agent for treatment of dyslipidemia and diabetes[1]. |
| Molecular Weight | 901.43 |
| Formula | C50H56MgN2O8S2 |
| Cas No. | 1639792-20-3 |
| Smiles | C(C)O1[Mg+2]2(O(CC)C(CC3=CC=C(OCCN4C(=CC=C4C)C5=CC=C(SC)C=C5)C=C3)C(=O)[O-]2)[O-]C(=O)C1CC6=CC=C(OCCN7C(=CC=C7C)C8=CC=C(SC)C=C8)C=C6 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 112.5 mg/mL (124.8 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.